By evaluating the most promising medical and scientific research, InvestBio seeks to single out the best venture capital and private equity opportunities for our clients.

Biotechnology venture capital is the driving force behind the funding of cutting edge technologies and current advances in the field of medical science. The potential reward of a successful biotech drug or treatment that reaches blockbuster status is enormous; not only to patients and the medical community, but to our qualified investors as well.

To achieve this, InvestBio identifies, selects, structures and manages these targeted opportunities, potentially allowing us to create a rewarding outcome for all parties involved.

InvestBio is a wholly owned subsidiary of DPEC Partners.